Does cognitive dysfunction correlate with neurofilament light polypeptide levels in the CSF of patients with multiple sclerosis?

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Sage Publications Country of Publication: England NLM ID: 0346411 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-2300 (Electronic) Linking ISSN: 03000605 NLM ISO Abbreviation: J Int Med Res Subsets: MEDLINE
    • Publication Information:
      Publication: Nov. 2012- : London : Sage Publications
      Original Publication: Northampton, Eng., Cambridge Medical Publications ltd.
    • Subject Terms:
      Biomarkers/*cerebrospinal fluid ; Cognitive Dysfunction/*pathology ; Multiple Sclerosis/*complications ; Neurofilament Proteins/*cerebrospinal fluid; Adult ; Case-Control Studies ; Cognitive Dysfunction/cerebrospinal fluid ; Cognitive Dysfunction/etiology ; Female ; Humans ; Male ; Prognosis
    • Abstract:
      Objective: To investigate whether neurofilament light polypeptide (NfL) level in cerebrospinal fluid (CSF), currently a prognostic biomarker of neurodegeneration in patients with multiple sclerosis (MS), may be a potential biomarker of cognitive dysfunction in MS.
      Methods: This observational case-control study included patients with MS. CSF levels of NfL were determined using enzyme-linked immunosorbent assay. Cognitive function was measured with the Brief International Cognitive Assessment for MS (BICAMS) battery and Paced Auditory Serial Addition Test (PASAT3), standardized to the Greek population.
      Results: Of 39 patients enrolled (aged 42.7 ± 13.6 years), 36% were classified as cognitively impaired according to BICAMS z-scores (-0.34 ± 1.13). Relapsing MS was significantly better than progressive forms regarding BICAMS z-score (mean difference [MD] 1.39; 95% confidence interval [CI] 0.54, 2.24), Symbol Digit Modality Test score (MD 1.73; 95% CI 0.46, 3.0) and Greek Verbal Learning Test (MD 1.77; 95% CI 0.82, 2.72). An inversely proportional association between CSF NfL levels and BICAMS z-scores was found in progressive forms of MS (r p  = -0.944).
      Conclusions: This study provides preliminary evidence for an association between CSF NfL levels and cognition in progressive forms of MS, which requires validation in larger samples.
    • References:
      Ann N Y Acad Sci. 2000 Jun;908:244-54. (PMID: 10911963)
      Arch Neurol. 2001 Oct;58(10):1602-6. (PMID: 11594918)
      Hybrid Hybridomics. 2002 Feb;21(1):53-9. (PMID: 11991817)
      Behav Neurol. 2003;14(1-2):39-45. (PMID: 12719637)
      Brain Res. 2003 Oct 10;987(1):25-31. (PMID: 14499942)
      Neurology. 2003 Dec 23;61(12):1720-5. (PMID: 14694036)
      Neurology. 2004 Nov 9;63(9):1586-90. (PMID: 15534240)
      Mult Scler. 2004 Dec;10(6):675-8. (PMID: 15584493)
      J Int Neuropsychol Soc. 2005 Sep;11(5):574-83. (PMID: 16212684)
      Physiology (Bethesda). 2006 Feb;21:38-47. (PMID: 16443821)
      Neurology. 2006 Mar 14;66(5):685-92. (PMID: 16534104)
      J Neurol. 2006 Aug;253(8):1002-10. (PMID: 16609812)
      J Neurol Sci. 2006 Jun 15;245(1-2):187-94. (PMID: 16643951)
      Mult Scler. 2007 Jan;13(1):52-7. (PMID: 17294611)
      Mult Scler. 2007 Jan;13(1):124-7. (PMID: 17294621)
      Parkinsonism Relat Disord. 2007 Dec;13(8):480-2. (PMID: 17448720)
      Mult Scler. 2007 Sep;13(8):1004-10. (PMID: 17623735)
      Neurobiol Dis. 2008 Dec;32(3):461-70. (PMID: 18804534)
      Lancet Neurol. 2008 Dec;7(12):1139-51. (PMID: 19007738)
      Brain Res Bull. 2009 Oct 28;80(4-5):282-95. (PMID: 19539727)
      J Immunol Methods. 2010 Jan 31;352(1-2):23-31. (PMID: 19857497)
      Neurology. 2009 Dec 1;73(22):1914-22. (PMID: 19949037)
      Neurology. 1991 May;41(5):685-91. (PMID: 2027484)
      Neurology. 2010 Oct 19;75(16):1428-31. (PMID: 20956787)
      Ann Neurol. 2011 Jan;69(1):83-9. (PMID: 21280078)
      J Neurol Sci. 2011 May 15;304(1-2):117-21. (PMID: 21349546)
      Expert Rev Neurother. 2011 Mar;11(3):425-32. (PMID: 21375447)
      Ann Neurol. 2011 Feb;69(2):292-302. (PMID: 21387374)
      Mult Scler. 2012 Jun;18(6):891-8. (PMID: 22190573)
      Psychiatriki. 2009 Oct;20(4):312-8. (PMID: 22218232)
      BMC Neurol. 2012 Jul 16;12:55. (PMID: 22799620)
      PLoS One. 2013 May 07;8(5):e63172. (PMID: 23667585)
      Mult Scler. 2013 Aug;19(9):1122-7. (PMID: 23897894)
      Int J Rehabil Res. 2014 Sep;37(3):271-6. (PMID: 24557490)
      Neurology. 2014 Jul 15;83(3):278-86. (PMID: 24871874)
      Lancet Neurol. 2015 Mar;14(3):302-17. (PMID: 25662900)
      Mult Scler. 2015 Apr;21(5):550-61. (PMID: 25732842)
      Mol Psychiatry. 2015 Aug;20(8):986-94. (PMID: 25869803)
      Neural Plast. 2015;2015:481574. (PMID: 26064692)
      Mult Scler Relat Disord. 2015 Jul;4(4):291-5. (PMID: 26195045)
      PLoS One. 2015 Aug 28;10(8):e0135886. (PMID: 26317831)
      Mult Scler Relat Disord. 2016 Sep;9:68-72. (PMID: 27645348)
      Mult Scler. 2017 Aug;23(9):1258-1267. (PMID: 27738090)
      Ann Neurol. 2017 Jun;81(6):857-870. (PMID: 28512753)
      Mult Scler. 2018 Jul;24(8):1046-1054. (PMID: 28627962)
      Int J Neuropsychopharmacol. 2017 Aug 1;20(8):624-633. (PMID: 28898959)
      Eur J Neurol. 2018 Jan;25(1):192-195. (PMID: 29053884)
      Neurology. 1983 Nov;33(11):1444-52. (PMID: 6685237)
      J Neurol Neurosurg Psychiatry. 1998 Apr;64(4):455-62. (PMID: 9576535)
      Prog Nucleic Acid Res Mol Biol. 1998;61:1-23. (PMID: 9752717)
    • Contributed Indexing:
      Keywords: BICAMS; Biomarkers; cognitive dysfunction; multiple sclerosis; neurofilament-light
    • Accession Number:
      0 (Biomarkers)
      0 (Neurofilament Proteins)
      0 (neurofilament protein L)
    • Publication Date:
      Date Created: 20190416 Date Completed: 20191206 Latest Revision: 20200225
    • Publication Date:
      20240628
    • Accession Number:
      PMC6567748
    • Accession Number:
      10.1177/0300060519840550
    • Accession Number:
      30982375